Page 10 - பல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Farxiga Gets FDA Greenlight in CKD Prevention

FDA expanded the indication for dapagliflozin (Farxiga) into chronic kidney disease (CKD). The drug, which first entered the market for type 2 diabetes in 2014, was approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression. CKD has a significant unmet need for therapies that slow disease progression and improve outcomes, said Aliza Thompson, MD, deputy director of the Division of Cardiology and Nephrology at the FDA s Center for Drug Evaluation and Research, in a statement. Today s approval of Farxiga for the treatment of chronic kidney disease is an important step forward in helping people living with kidney disease.

Hiddo heerspinkAliza thompsonDivision of cardiologyUniversity medical center groningenDrug evaluationபிரிவு ஆஃப் இருதயவியல்பல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந்மருந்து மதிப்பீடு

GATT announces first-in-man use of GATT-Patch , a hemostatic sealant patch, by Radboud university medical center Nijmegen

Share this article Share this article NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc). This first patient marks the start of a multicenter clinical trial that will be conducted by three leading academic medical centers in the Netherlands: Radboudumc, The University Medical Center Groningen, who have both already treated patients in the trial, and Erasmus Medical Centrum Rotterdam Mis intending to join shortly. GATT Technologies offices in Nijmegen

Johan benderGeert van gansewinkelPorte university medical center groningenVerhoef erasmus medical centerStuart headChief medical officerUniversity medical center groningenErasmus medical centerGatt technologiesஜோஹன் பெண்டர்ஸ்டூவர்ட் தலைதலைமை மருத்துவ அதிகாரிபல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந்ஈராஸ்மஸ் மருத்துவ மையம்க்யாட் தொழில்நுட்பங்கள்

Biotinylated Heparan Sulfate Antibodies

Biotinylated Heparan Sulfate Antibodies AMSBIO has launched two new biotinylated formats of the 10E4 Heparan Sulfate antibody (high and low biotin) along with a starter pack to allow scientists to test both formats at a reduced cost. Immunofluorescence staining of human kidney cortex using biotinylated 10E4 from AMSBIO (green), nuclei counterstained in blue. Image courtesy of Jacob van den Born (University Medical Center Groningen, Netherlands). Heparan Sulfate (HS) is a highly sulfated linear polysaccharide that is attached to a core protein to form HS Proteoglycans on the cell membrane or in the extracellular matrix. It is involved in important biological processes due to it displaying specific interactions with many biologically active proteins. In particular, HS has emerged as a key factor in infection by the SARS-CoV-2 virus, which is the cause of the COVID-19 coronavirus pandemic.

Born university medical center groningenUniversity medical center groningenHeparan sulfateபல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந்

GATT announces first-in-man use of GATT-Patch , a hemostatic sealant patch, by Radboud university medical center Nijmegen

GATT announces first-in-man use of GATT-Patch , a hemostatic sealant patch, by Radboud university medical center Nijmegen
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Johan benderGeert van gansewinkelPorte university medical center groningenVerhoef erasmus medical centerStuart headChief medical officerUniversity medical center groningenErasmus medical centerஜோஹன் பெண்டர்ஸ்டூவர்ட் தலைதலைமை மருத்துவ அதிகாரிபல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந்ஈராஸ்மஸ் மருத்துவ மையம்

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF
tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.

University of adelaideSouth australiaUnited kingdomDennis lauMichiel rienstraPhd university medical center groningenEuropean heart rhythm association congressUniversity medical center groningenRoyal adelaide hospitalதெற்கு ஆஸ்திரேலியாஒன்றுபட்டது கிஂக்டம்டென்னிஸ் லாவ்ஃப்ட் பல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந்ஐரோப்பிய இதயம் தாளம் சங்கம் காங்கிரஸ்பல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந்